NONOF:OTCMKTS
Novo Nordisk A/S
$38.40
arrow_upward
+0.39%(+0.15) 1D
Sep 24, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NONOF...
Open
$38.41
High
$38.75
Low
$38.10
Mkt. cap
132.52B
Avg. vol.
98.79K
Volume
1.01M
52-wk high
$64.75
52-wk low
$34.00
Beta
0.63
Shares outstanding
3.39B
No. of employees
67K
Open
$38.41
High
$38.75
Low
$38.10
Mkt. cap
132.52B
Avg. vol.
98.79K
Volume
1.01M
52-wk high
$64.75
52-wk low
$34.00
Beta
0.63
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
MarketWatch
·
34 minutes ago
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Global Banking & Finance Review
·
1 hour ago
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
AD HOC NEWS
·
4 hours ago
Novo-Nordisk stock falls 3.12 percent ahead of the open
The Motley Fool
·
11 hours ago
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Profile
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Novo's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com